Transformation Subsection C.4 Targeted literature General Australian population D.4 The disutility D.6 review for utility of males aged 61-70y, 0.82; associated with values low/intermediate risk PCa on prostate biopsy will AS, 0.796; high/intermediate be varied in risk PCa receiving Active sensitivity analyses, treatment/ follow-up, 0.789; between 0 and 0.05, consistent with the disutility of biopsy, 0.035; assessment of acute sepsis, 0.47; erectile MRIGB (CA 1424). dysfunction, 0.10; urinary incontinence, 0.20 Other Subsection C.5 Literature review mpMRI: no adverse events. D.4 None NA for the frequencies Biopsy: 1.2% sepsis. of adverse events. Prostate cancer treatment: 25.9% erectile dysfunction disutility) and 0.55% urinary incontinence (1-year disutility). AS = active surveillance, CI = confidence interval, mpMRI = multiparametric MRI, PCa = prostate cancer, MRIGB = MRI guided biopsy, CA = contracted assessment.
Transformation Subsection C.4 Targeted literature review for utility values General Australian population of males aged 61-70y, 0.82; low/intermediate risk PCa on AS, 0.796; high/intermediate risk PCa receiving Active treatment/ follow-up, 0.789; disutility of biopsy, 0.035; acute sepsis, 0.47; erectile dysfunction, 0.10; urinary incontinence, 0.20 D.4 The disutility associated with prostate biopsy will be varied in sensitivity analyses, between 0 and 0.05, consistent with the assessment of MRIGB (CA 1424). D.6 Other Subsection C.5 Literature review for the frequencies of adverse events. mpMRI: no adverse events. Biopsy: 1.2% sepsis. Prostate cancer treatment: 25.9% erectile dysfunction disutility) and 0.55% urinary incontinence (1-year disutility). D.4 None NA AS = active surveillance, CI = confidence interval, mpMRI = multiparametric MRI, PCa = prostate cancer, MRIGB = MRI guided biopsy, CA = contracted assessment.
1397_Final_MSAC_Assessment_Report.docx